Chronic Disease Compounding: Diabetes, Hypertension, Obesity, and the Predictable Trajectory Most Plans Watch Happen

Well-managed type 2 diabetes costs $10,000 to $15,000 per year in medical and pharmacy claims. Poorly managed diabetes with complications costs $50,000 to $100,000 or more. The difference is not random variation. It is a predictable trajectory visible in claims data three to five years before high-cost complications arrive. The member whose A1c creeps from 7.2 to 8.5 to 9.8 over four years is not a surprise high-cost claimant when diabetic nephropathy appears. The claims data showed rising lab values, irregular medication fills, declining engagement with primary care. The trajectory was visible. The plan watched it happen.

The American Diabetes Association’s 2022 economic cost study documented that people with diagnosed diabetes have medical expenditures 2.6 times higher than people without diabetes, averaging $19,736 per year compared to $7,714. The excess cost attributable to diabetes is $12,022 per person per year. Total U.S. costs of diagnosed diabetes reached $412.9 billion in 2022, including $306.6 billion in direct medical costs. One in four healthcare dollars in the United States goes to diabetes care. The cost has increased 35 percent over the past decade after adjusting for inflation.

Chronic disease compounding is the cost driver most amenable to intervention and least addressed by current plan design. The gap between what claims data reveals about deteriorating chronic disease trajectories and what small group TPAs do with that information defines the opportunity. The infrastructure to identify at-risk members exists. The disease management programs to intervene are documented. The problem is that small group plans rarely connect the two.

The Three Conditions and Their Prevalence

#

Type 2 diabetes, hypertension, and obesity are the three most prevalent chronic conditions in commercially insured working-age populations. They are often comorbid. A member with all three has a fundamentally different cost profile than a member with any one alone.

The CDC National Health Interview Survey documents chronic condition prevalence by age and insurance status. Among commercially insured adults aged 45 to 64, approximately 12 percent have diagnosed diabetes, 35 percent have diagnosed hypertension, and 42 percent have obesity. Approximately 25.5 million Americans have diagnosed diabetes as of 2022. The prevalence is higher in lower-income populations and in physically demanding industries, both of which are concentrated in the level funded market.

For a 25-person level funded plan with typical age distribution, the statistical expectation is three to four members with diabetes, eight to nine with hypertension, and ten to eleven with obesity. The conditions overlap. Obesity increases the risk of developing both diabetes and hypertension. Diabetes accelerates cardiovascular disease. Hypertension worsens diabetic kidney disease. Two to three members in a typical small group carry all three conditions simultaneously, creating a cost profile that compounds across each diagnosis.

The level funded market’s industry concentration amplifies the prevalence. Construction, landscaping, manufacturing, hospitality, and home health, the industries where level funded adoption is growing fastest, carry higher rates of obesity, diabetes, and hypertension than professional services. The blue-collar small employer documented in LFP-04.06 does not face national-average chronic disease prevalence. It faces the higher prevalence associated with physically demanding work, lower health literacy, reduced access to preventive care, and the dietary patterns common in lower-wage workforces. A 20-person landscaping company may have five to six members with obesity and three with diabetes rather than the national averages. The plan’s chronic disease cost exposure exceeds what national prevalence data would suggest.

The Compounding Trajectory

#

The cost trajectory from managed to unmanaged chronic disease is predictable, documented, and visible in claims data at every stage.

Diabetes follows a characteristic progression. Controlled on oral medication (A1c under 7, metformin and possibly a second agent), the member costs $8,000 to $12,000 annually for medications, monitoring, and routine care. As control deteriorates (A1c 7 to 8), medication intensifies. A GLP-1 receptor agonist or SGLT2 inhibitor adds $8,000 to $16,000 annually depending on the specific agent. As control deteriorates further (A1c above 8.5), insulin therapy begins. Insulin adds $8,000 to $25,000 annually depending on the regimen and whether biosimilar insulins are used.

The complication stage changes the cost profile entirely. Diabetic nephropathy requiring specialist monitoring costs $15,000 to $25,000 annually. Progression to end-stage renal disease requiring dialysis costs $80,000 to $120,000 annually; the United States Renal Data System documents dialysis as one of the highest per-patient cost categories in U.S. healthcare. Diabetic retinopathy requiring treatment costs $10,000 to $30,000 per year. Peripheral vascular disease requiring intervention costs $30,000 to $80,000. Foot amputation costs $40,000 to $100,000 for the surgical episode plus ongoing wound care, prosthetics, and rehabilitation.

The cumulative cost differential between well-managed diabetes over a decade and poorly managed diabetes progressing to complications is $300,000 to $500,000 per member. This is not a modeling exercise. It is the documented cost trajectory that claims data makes visible years before the high-cost stage arrives.

Hypertension follows a parallel trajectory. Controlled on one to two antihypertensive agents (blood pressure under 130/80), the member costs $3,000 to $6,000 annually for medications and monitoring. As control deteriorates, medication intensifies. Four or more agents indicate resistant hypertension and raise the cost and complexity of management. The complication stage is acute and expensive. A myocardial infarction costs $50,000 to $150,000 for acute hospitalization plus $20,000 to $50,000 annually for ongoing cardiac care. A stroke costs $50,000 to $200,000 for the acute episode plus ongoing rehabilitation, home health, and long-term medication. Congestive heart failure, driven by years of uncontrolled hypertension, generates $20,000 to $50,000 annually in ongoing management costs and recurrent hospitalizations. The distinction between the controlled hypertensive member costing $5,000 per year and the member who presents with a stroke costing $150,000 is the same distinction that applies to diabetes: a predictable trajectory that claims data documented for years before the acute event.

Obesity operates as an amplifier. It increases the cost of every comorbid condition. Surgical procedures cost more in obese patients due to longer operative times, higher complication rates, and extended recovery. MSK conditions documented in LFP-09.07 are more prevalent and more expensive in obese patients. Sleep apnea requiring CPAP adds $2,000 to $4,000 annually. The interaction between obesity and the other two conditions is bidirectional: obesity worsens both diabetes and hypertension, while the medications used to treat diabetes and hypertension can themselves affect weight. The GLP-1 drugs documented in LFP-09.03 address obesity directly but at $12,000 to $16,000 per year (declining to approximately $8,000 after the 2027 list price reduction), creating a new cost layer even as they potentially reduce downstream chronic disease progression.

The Visibility in Claims Data

#

The trajectory from managed to unmanaged chronic disease is not hidden. It is visible in claims data years before high-cost complications arrive. The visibility creates the intervention opportunity.

Rising A1c is visible through lab claims. When a member’s glycated hemoglobin test shows progression from 7.0 to 7.5 to 8.2 across three annual tests, the trajectory is documented in claims. Medication claims show the response: new prescriptions, changed dosages, additional agents. The combination of worsening labs and intensifying medication signals a member whose disease control is deteriorating.

Irregular medication fills are visible through pharmacy claims. A member who should refill a 30-day diabetes medication twelve times per year but fills only eight times is non-adherent. Non-adherence predicts progression. The pharmacy claims show the pattern clearly, and a TPA with real-time pharmacy data can flag non-adherent members within weeks of a missed refill.

Declining primary care engagement is visible through professional claims. A diabetic member should have at least two primary care visits annually for routine monitoring. A member with zero PCP visits in 18 months is not engaged with care. The gap is visible in claims data and correlates strongly with the trajectory toward complications.

A TPA with real-time claims analytics can identify members on deteriorating trajectories through these indicators. The identification creates the opportunity to intervene: outreach, care coordination, disease management program enrollment, barriers assessment. The Milliman research on integrated medical-behavioral healthcare documented that collaborative care programs reduced total healthcare costs by approximately 10 percent over four years, with savings in every service category. The intervention works. Most small group TPAs do not have the analytical capability to identify the candidates. They process claims without identifying patterns. The trajectory continues until complications arrive and the costs become impossible to ignore.

The Cost Differential

#

The magnitude of the chronic disease intervention opportunity is large relative to every other cost driver in this series.

The $300,000 to $500,000 cumulative cost differential between well-managed and poorly managed diabetes over a decade exceeds most specialty drug exposures (LFP-09.01). It exceeds most pregnancy variances (LFP-09.02). It compounds across every member with chronic disease in the plan. In a 25-person plan with three diabetic members, the aggregate chronic disease trajectory represents a potential claims differential of $120,000 to $240,000 annually when complications arrive.

Preventing one member’s chronic disease progression from crossing the complication threshold saves the plan $40,000 to $80,000 in the year when complications would otherwise materialize. The intervention cost is a fraction: disease management program enrollment costs $200 to $500 per member per year, care coordination for high-risk members adds $1,000 to $2,000, pharmacy optimization through biosimilar insulin and generic medication selection may add no incremental cost.

The ROI calculation favors chronic disease intervention. The challenge is infrastructure. Identifying at-risk members requires claims analytics capability that most small group TPAs do not possess. Intervening requires care coordination resources. Maintaining engagement requires ongoing outreach. Building this infrastructure across a TPA’s book of business produces returns that justify the investment, but the TPA must build it before the returns materialize. The alternative is absorbing the cost of complications at renewal: higher stop loss premiums, lasered members, and rising monthly contributions that eventually price the employer out of level funded coverage.

The plans that address chronic disease compounding systematically will have fundamentally different cost profiles than the plans that watch it happen. The trajectory is visible. The intervention points are documented. The cost differential is enormous. The gap between what is known and what is done defines the chronic disease opportunity in small group plans. Series 10 examines chronic disease interception programs in operational detail.